Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Mtb PKNA/PKNB Dual Inhibition Provides Selectivity Advantages for Inhibitor Design To Minimize Host Kinase Interactions.

Wang T, Bemis G, Hanzelka B, Zuccola H, Wynn M, Moody CS, Green J, Locher C, Liu A, Gao H, Xu Y, Wang S, Wang J, Bennani YL, Thomson JA, Müh U.

ACS Med Chem Lett. 2017 Nov 28;8(12):1224-1229. doi: 10.1021/acsmedchemlett.7b00239. eCollection 2017 Dec 14.

2.

Discovery of Novel, Orally Bioavailable β-Amino Acid Azaindole Inhibitors of Influenza PB2.

Farmer LJ, Clark MP, Boyd MJ, Perola E, Jones SM, Tsai A, Jacobs MD, Bandarage UK, Ledeboer MW, Wang T, Deng H, Ledford B, Gu W, Duffy JP, Bethiel RS, Shannon D, Byrn RA, Leeman JR, Rijnbrand R, Bennett HB, O'Brien C, Memmott C, Nti-Addae K, Bennani YL, Charifson PS.

ACS Med Chem Lett. 2017 Jan 20;8(2):256-260. doi: 10.1021/acsmedchemlett.6b00486. eCollection 2017 Feb 9.

3.

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases.

Farmer LJ, Ledeboer MW, Hoock T, Arnost MJ, Bethiel RS, Bennani YL, Black JJ, Brummel CL, Chakilam A, Dorsch WA, Fan B, Cochran JE, Halas S, Harrington EM, Hogan JK, Howe D, Huang H, Jacobs DH, Laitinen LM, Liao S, Mahajan S, Marone V, Martinez-Botella G, McCarthy P, Messersmith D, Namchuk M, Oh L, Penney MS, Pierce AC, Raybuck SA, Rugg A, Salituro FG, Saxena K, Shannon D, Shlyakter D, Swenson L, Tian SK, Town C, Wang J, Wang T, Wannamaker MW, Winquist RJ, Zuccola HJ.

J Med Chem. 2015 Sep 24;58(18):7195-216. doi: 10.1021/acs.jmedchem.5b00301. Epub 2015 Sep 10.

PMID:
26230873
4.

Discovery and Characterization of a Water-Soluble Prodrug of a Dual Inhibitor of Bacterial DNA Gyrase and Topoisomerase IV.

O'Dowd H, Shannon DE, Chandupatla KR, Dixit V, Engtrakul JJ, Ye Z, Jones SM, O'Brien CF, Nicolau DP, Tessier PR, Crandon JL, Song B, Macikenas D, Hanzelka BL, Le Tiran A, Bennani YL, Charifson PS, Grillot AL.

ACS Med Chem Lett. 2015 Jun 22;6(7):822-6. doi: 10.1021/acsmedchemlett.5b00196. eCollection 2015 Jul 9.

5.

Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b.

Giroux S, Bilimoria D, Cadilhac C, Cottrell KM, Denis F, Dietrich E, Ewing N, Henderson JA, L'Heureux L, Mani N, Morris M, Nicolas O, Reddy TJ, Selliah S, Shawgo RS, Xu J, Chauret N, Berlioz-Seux F, Chan LC, Das SK, Grillot AL, Bennani YL, Maxwell JP.

Bioorg Med Chem Lett. 2015 Feb 15;25(4):940-3. doi: 10.1016/j.bmcl.2014.12.044. Epub 2014 Dec 29.

PMID:
25597006
6.

Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 1: C2-symmetric inhibitors with diyne and biphenyl linkers.

Giroux S, Bilimoria D, Cadilhac C, Cottrell KM, Denis F, Dietrich E, Ewing N, Henderson JA, L'Heureux L, Mani N, Morris M, Nicolas O, Reddy TJ, Selliah S, Shawgo RS, Xu J, Chauret N, Berlioz-Seux F, Chan LC, Das SK, Grillot AL, Bennani YL, Maxwell JP.

Bioorg Med Chem Lett. 2015 Feb 15;25(4):936-9. doi: 10.1016/j.bmcl.2014.12.046. Epub 2014 Dec 30.

PMID:
25595681
7.

Benzimidazole-containing HCV NS5A inhibitors: effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potency.

Henderson JA, Bilimoria D, Bubenik M, Cadilhac C, Cottrell KM, Dietrich E, Denis F, Ewing N, Falardeau G, Giroux S, Grey R Jr, L'Heureux L, Liu B, Mani N, Morris M, Nicolas O, Pereira OZ, Poisson C, Govinda Rao B, Reddy TJ, Selliah S, Shawgo RS, Vaillancourt L, Wang J, Yannopoulos CG, Chauret N, Berlioz-Seux F, Chan LC, Das SK, Grillot AL, Bennani YL, Maxwell JP.

Bioorg Med Chem Lett. 2015 Feb 15;25(4):944-7. doi: 10.1016/j.bmcl.2014.12.045. Epub 2014 Dec 20.

PMID:
25577041
8.

Synthesis and evaluation of NS5A inhibitors containing diverse heteroaromatic cores.

Henderson JA, Bilimoria D, Bubenik M, Cadilhac C, Cottrell KM, Denis F, Dietrich E, Ewing N, Falardeau G, Giroux S, L'Heureux L, Liu B, Mani N, Morris M, Nicolas O, Pereira OZ, Poisson C, Reddy TJ, Selliah S, Shawgo RS, Vaillancourt L, Wang J, Xu J, Chauret N, Berlioz-Seux F, Chan LC, Das SK, Grillot AL, Bennani YL, Maxwell JP.

Bioorg Med Chem Lett. 2015 Feb 15;25(4):948-51. doi: 10.1016/j.bmcl.2014.12.042. Epub 2014 Dec 22.

PMID:
25577039
9.

Drug hunters incorporated! Is there a formula?

Bennani YL.

Drug Discov Today. 2015 Jan;20(1):1-2. doi: 10.1016/j.drudis.2014.11.012. Epub 2014 Nov 24. No abstract available.

PMID:
25463035
10.

Natural products in medicine: transformational outcome of synthetic chemistry.

Szychowski J, Truchon JF, Bennani YL.

J Med Chem. 2014 Nov 26;57(22):9292-308. doi: 10.1021/jm500941m. Epub 2014 Sep 10. Review.

PMID:
25144261
11.

Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.

Clark MP, Ledeboer MW, Davies I, Byrn RA, Jones SM, Perola E, Tsai A, Jacobs M, Nti-Addae K, Bandarage UK, Boyd MJ, Bethiel RS, Court JJ, Deng H, Duffy JP, Dorsch WA, Farmer LJ, Gao H, Gu W, Jackson K, Jacobs DH, Kennedy JM, Ledford B, Liang J, Maltais F, Murcko M, Wang T, Wannamaker MW, Bennett HB, Leeman JR, McNeil C, Taylor WP, Memmott C, Jiang M, Rijnbrand R, Bral C, Germann U, Nezami A, Zhang Y, Salituro FG, Bennani YL, Charifson PS.

J Med Chem. 2014 Aug 14;57(15):6668-78. doi: 10.1021/jm5007275. Epub 2014 Jul 24.

PMID:
25019388
12.

Discovery of Thienoimidazole-Based HCV NS5A Genotype 1a and 1b Inhibitors.

Giroux S, Xu J, Reddy TJ, Morris M, Cottrell KM, Cadilhac C, Henderson JA, Nicolas O, Bilimoria D, Denis F, Mani N, Ewing N, Shawgo R, L'Heureux L, Selliah S, Chan L, Chauret N, Berlioz-Seux F, Namchuk MN, Grillot AL, Bennani YL, Das SK, Maxwell JP.

ACS Med Chem Lett. 2013 Jan 27;5(3):240-3. doi: 10.1021/ml300461f. eCollection 2014 Mar 13.

13.

Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.

Bennani YL, Gu W, Canales A, Díaz FJ, Eustace BK, Hoover RR, Jiménez-Barbero J, Nezami A, Wang T.

J Med Chem. 2012 Mar 8;55(5):1920-5. doi: 10.1021/jm200848t. Epub 2012 Feb 27.

PMID:
22320354
14.

Drug discovery in the next decade: innovation needed ASAP.

Bennani YL.

Drug Discov Today. 2012 Feb;17 Suppl:S31-44. doi: 10.1016/j.drudis.2011.12.007. Epub 2011 Dec 10.

PMID:
22178889
15.

Drug discovery in the next decade: innovation needed ASAP.

Bennani YL.

Drug Discov Today. 2011 Sep;16(17-18):779-92. doi: 10.1016/j.drudis.2011.06.004. Epub 2011 Jun 15. Review.

PMID:
21704185
16.

Investigation of 4-piperidinols as novel H3 antagonists.

Anderson JT, Campbell M, Wang J, Brunden KR, Harrington JJ, Stricker-Krongrad A, Song J, Doucette C, Murphy S, Bennani YL.

Bioorg Med Chem Lett. 2010 Nov 1;20(21):6246-9. doi: 10.1016/j.bmcl.2010.08.099. Epub 2010 Aug 24.

PMID:
20833043
17.

3-Indolyl sultams as selective CRTh2 antagonists.

Tumey LN, Robarge MJ, Gleason E, Song J, Murphy SM, Ekema G, Doucette C, Hanniford D, Palmer M, Pawlowski G, Danzig J, Loftus M, Hunady K, Sherf B, Mays RW, Stricker-Krongrad A, Brunden KR, Bennani YL, Harrington JJ.

Bioorg Med Chem Lett. 2010 Jun 1;20(11):3287-90. doi: 10.1016/j.bmcl.2010.04.046. Epub 2010 Apr 14.

PMID:
20457519
18.

Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole.

Wang T, Duffy JP, Wang J, Halas S, Salituro FG, Pierce AC, Zuccola HJ, Black JR, Hogan JK, Jepson S, Shlyakter D, Mahajan S, Gu Y, Hoock T, Wood M, Furey BF, Frantz JD, Dauffenbach LM, Germann UA, Fan B, Namchuk M, Bennani YL, Ledeboer MW.

J Med Chem. 2009 Dec 24;52(24):7938-41. doi: 10.1021/jm901383u.

PMID:
20014869
19.

A novel chemotype of kinase inhibitors: Discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors.

Wang T, Ledeboer MW, Duffy JP, Salituro FG, Pierce AC, Zuccola HJ, Block E, Shlyakter D, Hogan JK, Bennani YL.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):153-6. doi: 10.1016/j.bmcl.2009.11.021. Epub 2009 Nov 12. Erratum in: Bioorg Med Chem Lett. 2010 Apr 15;20(8):2684. Salituro, Francesco G [added].

PMID:
19945871
20.

In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats.

Maltais F, Jung YC, Chen M, Tanoury J, Perni RB, Mani N, Laitinen L, Huang H, Liao S, Gao H, Tsao H, Block E, Ma C, Shawgo RS, Town C, Brummel CL, Howe D, Pazhanisamy S, Raybuck S, Namchuk M, Bennani YL.

J Med Chem. 2009 Dec 24;52(24):7993-8001. doi: 10.1021/jm901023f.

PMID:
19894743
21.

2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.

Ledeboer MW, Pierce AC, Duffy JP, Gao H, Messersmith D, Salituro FG, Nanthakumar S, Come J, Zuccola HJ, Swenson L, Shlyakter D, Mahajan S, Hoock T, Fan B, Tsai WJ, Kolaczkowski E, Carrier S, Hogan JK, Zessis R, Pazhanisamy S, Bennani YL.

Bioorg Med Chem Lett. 2009 Dec 1;19(23):6529-33. doi: 10.1016/j.bmcl.2009.10.053. Epub 2009 Oct 24.

PMID:
19857967
22.

Design of a new histamine H3 receptor antagonist chemotype: (3aR,6aR)-5-alkyl-1-aryl-octahydropyrrolo[3,4-b]pyrroles, synthesis, and structure-activity relationships.

Zhao C, Sun M, Bennani YL, Miller TR, Witte DG, Esbenshade TA, Wetter J, Marsh KC, Hancock AA, Brioni JD, Cowart MD.

J Med Chem. 2009 Aug 13;52(15):4640-9. doi: 10.1021/jm900480x.

PMID:
19588934
23.

The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.

Zhao C, Sun M, Bennani YL, Gopalakrishnan SM, Witte DG, Miller TR, Krueger KM, Browman KE, Thiffault C, Wetter J, Marsh KC, Hancock AA, Esbenshade TA, Cowart MD.

J Med Chem. 2008 Sep 11;51(17):5423-30. doi: 10.1021/jm8003625. Epub 2008 Aug 7.

PMID:
18683917
24.

A new family of histamine H3 receptor antagonists based on a natural product: discovery, SAR, and properties of the series.

Cowart M, Sun M, Zhao C, Witte DG, Miller TR, Krueger KM, Browman K, Fox GB, Bennani YL, Esbenshade TA, Hancock AA.

Inflamm Res. 2007 Apr;56 Suppl 1:S47-8. No abstract available.

PMID:
17806176
25.

4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.

Black LA, Nersesian DL, Sharma P, Ku YY, Bennani YL, Marsh KC, Miller TR, Esbenshade TA, Hancock AA, Cowart M.

Bioorg Med Chem Lett. 2007 Mar 1;17(5):1443-6. Epub 2006 Dec 1.

PMID:
17169555
26.

The design and synthesis of a tricyclic single-nitrogen scaffold that serves as a 5-HT2C receptor agonist.

Huck BR, Llamas L, Robarge MJ, Dent TC, Song J, Hodnick WF, Crumrine C, Stricker-Krongrad A, Harrington J, Brunden KR, Bennani YL.

Bioorg Med Chem Lett. 2006 Aug 1;16(15):4130-4. Epub 2006 Jun 5.

PMID:
16750364
27.

Evidence for tolerance following repeated dosing in rats with ciproxifan, but not with A-304121.

Pan JB, Yao BB, Miller TR, Kroeger PE, Bennani YL, Komater VA, Esbenshade TA, Hancock AA, Decker MW, Fox GB.

Life Sci. 2006 Aug 29;79(14):1366-79. Epub 2006 Apr 26.

PMID:
16730751
28.

The identification of pyrimidine-diazabicyclo[3.3.0]octane derivatives as 5-HT2C receptor agonists.

Huck BR, Llamas L, Robarge MJ, Dent TC, Song J, Hodnick WF, Crumrine C, Stricker-Krongrad A, Harrington J, Brunden KR, Bennani YL.

Bioorg Med Chem Lett. 2006 Jun 1;16(11):2891-4. Epub 2006 Mar 20.

PMID:
16546379
29.

Aza-retinoids as novel retinoid X receptor-specific agonists.

Farmer LJ, Marron KS, Canan Koch SS, Hwang CK, Kallel EA, Zhi L, Nadzan AM, Robertson DW, Bennani YL.

Bioorg Med Chem Lett. 2006 May 1;16(9):2352-6. Epub 2005 Dec 20.

PMID:
16364638
30.

Use of an inverse agonist radioligand [3H]A-317920 reveals distinct pharmacological profiles of the rat histamine H3 receptor.

Yao BB, Witte DG, Miller TR, Carr TL, Kang CH, Cassar S, Faghih R, Bennani YL, Surber BW, Hancock AA, Esbenshade TA.

Neuropharmacology. 2006 Mar;50(4):468-78. Epub 2005 Nov 28.

PMID:
16316670
31.

Identification of novel and improved antimitotic agents derived from noscapine.

Anderson JT, Ting AE, Boozer S, Brunden KR, Crumrine C, Danzig J, Dent T, Faga L, Harrington JJ, Hodnick WF, Murphy SM, Pawlowski G, Perry R, Raber A, Rundlett SE, Stricker-Krongrad A, Wang J, Bennani YL.

J Med Chem. 2005 Nov 17;48(23):7096-8.

PMID:
16279766
32.

Structure-activity relationships of arylbenzofuran H3 receptor antagonists.

Gfesser GA, Faghih R, Bennani YL, Curtis MP, Esbenshade TA, Hancock AA, Cowart MD.

Bioorg Med Chem Lett. 2005 May 16;15(10):2559-63.

PMID:
15863316
33.

Discovery of S-phase arresting agents derived from noscapine.

Anderson JT, Ting AE, Boozer S, Brunden KR, Danzig J, Dent T, Harrington JJ, Murphy SM, Perry R, Raber A, Rundlett SE, Wang J, Wang N, Bennani YL.

J Med Chem. 2005 Apr 21;48(8):2756-8.

PMID:
15828811
34.

Isosteric ramatroban analogs: selective and potent CRTH-2 antagonists.

Robarge MJ, Bom DC, Tumey LN, Varga N, Gleason E, Silver D, Song J, Murphy SM, Ekema G, Doucette C, Hanniford D, Palmer M, Pawlowski G, Danzig J, Loftus M, Hunady K, Sherf BA, Mays RW, Stricker-Krongrad A, Brunden KR, Harrington JJ, Bennani YL.

Bioorg Med Chem Lett. 2005 Mar 15;15(6):1749-53.

PMID:
15745833
35.

4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.

Cowart M, Faghih R, Curtis MP, Gfesser GA, Bennani YL, Black LA, Pan L, Marsh KC, Sullivan JP, Esbenshade TA, Fox GB, Hancock AA.

J Med Chem. 2005 Jan 13;48(1):38-55.

PMID:
15634000
36.

Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.

Esbenshade TA, Fox GB, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan L, Wetter J, Marsh K, Bennani YL, Cowart MD, Sullivan JP, Hancock AA.

J Pharmacol Exp Ther. 2005 Apr;313(1):165-75. Epub 2004 Dec 17.

PMID:
15608078
37.

Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist.

Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard ME, Komater VA, Miner H, Zhang M, Faghih R, Rueter LE, Bitner RS, Drescher KU, Wetter J, Marsh K, Lemaire M, Porsolt RD, Bennani YL, Sullivan JP, Cowart MD, Decker MW, Hancock AA.

J Pharmacol Exp Ther. 2005 Apr;313(1):176-90. Epub 2004 Dec 17.

PMID:
15608077
38.

The identification and optimization of a N-hydroxy urea series of flap endonuclease 1 inhibitors.

Tumey LN, Bom D, Huck B, Gleason E, Wang J, Silver D, Brunden K, Boozer S, Rundlett S, Sherf B, Murphy S, Dent T, Leventhal C, Bailey A, Harrington J, Bennani YL.

Bioorg Med Chem Lett. 2005 Jan 17;15(2):277-81.

PMID:
15603939
39.

The identification and optimization of 2,4-diketobutyric acids as flap endonuclease 1 inhibitors.

Tumey LN, Huck B, Gleason E, Wang J, Silver D, Brunden K, Boozer S, Rundlett S, Sherf B, Murphy S, Bailey A, Dent T, Leventhal C, Harrington J, Bennani YL.

Bioorg Med Chem Lett. 2004 Oct 4;14(19):4915-8.

PMID:
15341951
40.

Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.

Esbenshade TA, Fox GB, Krueger KM, Baranowski JL, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan JB, Faghih R, Bennani YL, Williams M, Hancock AA.

Biochem Pharmacol. 2004 Sep 1;68(5):933-45.

PMID:
15294456
41.

D-amino acid homopiperazine amides: discovery of A-320436, a potent and selective non-imidazole histamine H(3)-receptor antagonist.

Curtis MP, Dwight W, Pratt J, Cowart M, Esbenshade TA, Krueger KM, Fox GB, Pan JB, Pagano TG, Hancock AA, Faghih R, Bennani YL.

Arch Pharm (Weinheim). 2004 Apr;337(4):219-29.

PMID:
15146898
42.

Structure-activity relationships of A-331440: a new histamine-3 antagonist with anti-obesity properties.

Faghih R, Esbenshade TA, Krueger KM, Yao BB, Witte DG, Miller TM, Kang CH, Fox GB, Cowart M, Bennani YL, Hancock AA.

Inflamm Res. 2004 Mar;53 Suppl 1:S79-80. Epub 2004 Mar 5. No abstract available.

PMID:
15054629
43.

Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist.

Hancock AA, Bennani YL, Bush EN, Esbenshade TA, Faghih R, Fox GB, Jacobson P, Knourek-Segel V, Krueger KM, Nuss ME, Pan JB, Shapiro R, Witte DG, Yao BB.

Eur J Pharmacol. 2004 Mar 8;487(1-3):183-97.

PMID:
15033391
44.

A new class of potent non-imidazole H(3) antagonists: 2-aminoethylbenzofurans.

Cowart M, Pratt JK, Stewart AO, Bennani YL, Esbenshade TA, Hancock AA.

Bioorg Med Chem Lett. 2004 Feb 9;14(3):689-93.

PMID:
14741270
45.

Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 3: 5-Substituted 3-phenyl-1,2,4-oxadiazoles as potent antagonists.

Gfesser GA, Zhang H, Dinges J, Fox GB, Pan JB, Esbenshade TA, Yao BB, Witte D, Miller TR, Kang CH, Krueger KM, Bennani YL, Hancock AA, Faghih R.

Bioorg Med Chem Lett. 2004 Feb 9;14(3):673-6.

PMID:
14741266
46.

An efficient multigram synthesis of the potent histamine H3 antagonist GT-2331 and the reassessment of the absolute configuration.

Liu H, Kerdesky FA, Black LA, Fitzgerald M, Henry R, Esbenshade TA, Hancock AA, Bennani YL.

J Org Chem. 2004 Jan 9;69(1):192-4.

PMID:
14703397
47.

A new class of histamine H(3)-receptor antagonists: synthesis and structure-activity relationships of 7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolines.

Turner SC, Esbenshade TA, Bennani YL, Hancock AA.

Bioorg Med Chem Lett. 2003 Jul 7;13(13):2131-5.

PMID:
12798320
48.

D-alanine piperazine-amides: novel non-imidazole antagonists of the histamine H3 receptor.

Faghih R, Phelan K, Esbenshade TA, Miller TR, Kang CH, Krueger KM, Yao BB, Fox GB, Bennani YL, Hancock AA.

Inflamm Res. 2003 Apr;52 Suppl 1:S47-8. No abstract available.

PMID:
12755406
49.

In vitro pharmacological properties of two novel non-imidazole H3 receptor (H3R) antagonists.

Yao BB, Witte DG, Miller TR, Krueger KM, Carr TL, Kang CH, Faghih R, Bennani YL, Esbenshade TA, Hancock AA.

Inflamm Res. 2003 Apr;52 Suppl 1:S45-6. No abstract available.

PMID:
12755405
50.

Identification of novel H3 receptor (H3R) antagonists with cognition enhancing properties in rats.

Fox GB, Pan JB, Faghih R, Esbenshade TA, Lewis A, Bitner RS, Black LA, Bennani YL, Decker MW, Hancock AA.

Inflamm Res. 2003 Apr;52 Suppl 1:S31-2. No abstract available.

PMID:
12755398

Supplemental Content

Loading ...
Support Center